SCHEMBL5403605

SCHEMBL5403605

COc1ccc(-c2nc(Cn3ccnn3)cs2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.56
ALDH1A1 P00352 3/20 0.56
RAB9A P51151 2/20 0.56
TDP1 Q9NUW8 1/20 0.56
HPGD P15428 2/20 0.53
ABCB1 P08183 2/20 0.51
ABCC1 P33527 1/20 0.51
ABCG2 Q9UNQ0 1/20 0.51
ATP4A P20648 1/20 0.47
ATP4B P51164 1/20 0.47
MAPT P10636 6/20 0.45
TP53 P04637 1/20 0.44
POLB P06746 1/20 0.44
ATM Q13315 1/20 0.44
CYP19A1 P11511 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ADORA1 P30542 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5403596 0.83 CYP19A1 (0.45) KDM4EALDH1A1RAB9AHPGDATP4A
SCHEMBL5400344 0.81 CYP19A1 (0.42) KDM4EALDH1A1RAB9ATDP1ATP4A
SCHEMBL5401821 0.78 KDM4E (0.56) KDM4EALDH1A1RAB9ATDP1HPGD
SCHEMBL8865759 0.76 CYP19A1 (0.61) KDM4EALDH1A1RAB9AMAPTCYP19A1
SCHEMBL5389906 0.75 ENPP3 (0.44) KDM4ERAB9AABCB1ABCC1CYP19A1
SCHEMBL28294637 0.74 ALDH1A1 (0.47) KDM4EALDH1A1RAB9ATDP1HPGD
SCHEMBL202826 0.74 KDM4E (0.70) KDM4EALDH1A1RAB9ATDP1HPGD
SCHEMBL3370261 0.74 KDM4E (0.97) KDM4EALDH1A1RAB9ATDP1HPGD
SCHEMBL201951 0.74 KDM4E (0.70) KDM4EALDH1A1RAB9ATDP1HPGD
SCHEMBL3115301 0.73 RAB9A (0.56) KDM4EALDH1A1RAB9ATDP1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7259262-B2 Arylazole derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-08-21 US disclosed
EP-1680417-A1 1-'(E)-2-(PHENYL)ETHENYL-4-(ARYLALKOXY)-OXAZOLE OR -THIAZOLE COMPOUNDS AS HER-2 TYROSINE KINASES INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2006-07-19 EP disclosed
US-20050124670-A1 Novel arylazole derivatives, their manufacture and use as pharmaceutical agents F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2005-06-09 US disclosed
WO-2005040158-A1 1-′(E)-2-(PHENYL) ETHENYL-4-(ARYLALKOXY)-OXAZOLE OR - THIAZOLE COMPOUNDS AS HER-2 TYROSINE KINASES INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN - LA ROCHE AG (CH) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124670-A1 Novel arylazole derivatives, their manufacture and use as pharmaceutical agents CYP3A43, CYP3A5, CYP1A1 KDM4E 3571/4885ALDH1A1 66/4885RAB9A 1573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.